Long-Acting Agents in Severe COPD

Long-Acting Agents in Severe COPD

Program

Part 1: Choosing Single vs Dual Bronchodilator Therapy

Patient Case

GOLD COPD Multidimensional Assessment Approach

Standardized Tools: CAT and mMRC Dyspnea Scale

GOLD Therapeutic Recommendations

LAMA and LABA Result in Similar QoL Improvement

Patient Case

Relationship Between FEV1 and SGRQ

Symptomatic Response to Dual Bronchodilation Is Dependent on Baseline Symptom Burden

Meta-Analysis Favors Dual Bronchodilators Over Mono Components to Improve Exercise Capacity

Part 2: Choosing Dual vs Triple Bronchodilator Therapy

Patient Case

GOLD Therapeutic Recommendations

LAMA Reduces Exacerbations Compared With a LABA

FLAME: Probability of a First Mild, Moderate, or Severe Exacerbation on Treatment

IMPACT: ICS/LABA Decreased the Rate of On-Treatment Moderate/Severe Exacerbations vs LAMA/LABA

Inclusion/Exclusion Criteria for IMPACT

LABA/LAMA/ICS Decreases Exacerbations Compared With LAMA and LAMA/LABA

IMPACT: LABA/LAMA/ICS Reduces Moderate/Severe Exacerbations vs Individual Dual Combinations in Same Device

Patient Case

ICS Is Associated With Improved All-Cause Mortality (On-Treatment Data) but Increased Pneumonia in IMPACT

Risk Factors Associated With CXR-Confirmed Pneumonia in Patients With COPD Treated With ICS

Part 3: Does Eosinophil Count Influence Treatment Decision?

Patient Case

Patient Case

FLAME Subgroup Analysis by Circulating Eosinophils

Eosinophil Count Determines Response to BUD-FM as Compared With FM Alone

IMPACT: Rate of Moderate/Severe Exacerbations in the Non-ICS-Containing Arm (UMEC/VI) Increased With Baseline Blood Eosinophil Count

Mepolizumab in Eosinophilic COPD

Part 4: When Bronchodilation Is Not Sufficient -- Role of Oral Agents

Patient Case

GOLD Therapeutic Recommendations

Roflumilast Response Is Particularly Evident in COPD Patients With Distinct Phenotypes

Predictors of COPD Exacerbation Reduction in Response to Daily Azithromycin Therapy

Abbreviations

Abbreviations (cont)